<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01272180</url>
  </required_header>
  <id_info>
    <org_study_id>V102_03</org_study_id>
    <secondary_id>2010-023523-23</secondary_id>
    <nct_id>NCT01272180</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults</brief_title>
  <official_title>Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB With OMV + MenACWY Combination Vaccination Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and immunogenicity of combination vaccines as compared to
      the reference vaccines
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentages of Subjects With a Seroresponse Against N.Meningitidis Serogroups A,C,W-135,Y, After Receiving Different Formulations of MenABCWY Combination Vaccine.</measure>
    <time_frame>One month after the second vaccination (Day 91)</time_frame>
    <description>Non-inferiority of immune response of two doses of two different formulations of MenABCWY vaccine to a single dose of MenACWY vaccine as measured by the percentage of subjects with hSBA seroresponse against N.meningitidis serogroups A,C,W and Y.
Seroresponse is defined as:
For subjects with a pre-vaccination hSBA titer &lt; 1:4, a post-vaccination hSBA titer ≥ 1:8;
For subjects with a pre-vaccination hSBA titer ≥ 1:4, an increase in hSBA titer of at least four times the prevaccination titer.
Functional bactericidal antibodies directed against serogroups A,C,W,Y meningococci were measured with a serum bactericidal activity assay using human serum as the source of exogenous complement (hSBA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Desirability Index for Each Vaccine Group, Based on Immunogenicity and Reactogenicity Parameters.</measure>
    <time_frame>One month after the second vaccination (Day 91)</time_frame>
    <description>The overall desirability index (DI) used to identify the optimal formulation of the combination vaccine was based on immunogenicity and reactogenicity parameters (on a scale of 0 to 1, with 0 for an undesirable response and 1 for a highly desirable response) as follows: Between-group ratios of hSBA GMTs were calculated, adjusted for prevaccination titer and center, against serogroups A, C, W, and Y (ABCWY+OMV group or ABCWY+qOMV group vs. Placebo/ACWY group) and against the 4 serogroup B test strains (ABCWY+OMV group or ABCWY+qOMV group vs. rMenB+OMV group). Reactogenicity was measured by the percentage of doses associated with severe local and systemic solicited AEs within 3 days following vaccination. Each immunogenicity and reactogenicity endpoint was assigned its own DI based on predefined desirability functions. The overall DI was calculated using the weighted geometric mean of the DI values of each of the ten parameters to derive an overall DI for each formulation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Titers ≥ 1:8 Against N.Meningitidis Serogroups A,C,W-135 and Y, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.</measure>
    <time_frame>Day 1 and one month after second vaccination (Day 91)</time_frame>
    <description>Percentages of subjects with hSBA titers ≥ 1:8 against N.meningitidis serogroups A,C,W-135 and Y, after two doses of either ABCWY+OMV or ABCWY+qOMV combination vaccine or one dose of MenACWY vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The hSBA GMTs Against N.Meningitidis Serogroups A,C,W-135 and Y, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.</measure>
    <time_frame>Day 1 and one month after the second vaccination (Day 91)</time_frame>
    <description>The hSBA GMTs against N.meningitidis serogroups A,C,W-135 and Y, after two doses of either ABCWY+OMV or ABCWY+qOMV combination vaccine, or one dose of MenACWY vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Titers ≥ 1:5 and ≥ 1:8 Against N.Meningitidis Serogroup B, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.</measure>
    <time_frame>Day 1 and one month after the second vaccination (Day 91)</time_frame>
    <description>The percentages of subjects with hSBA titers ≥ 1:5 and ≥ 1:8 against four different strains of N.meningitidis serogroup B, after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With at Least 4-fold Increase in hSBA Titers Against N.Meningitidis Serogroup B, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.</measure>
    <time_frame>One month after the second vaccination (Day 91)</time_frame>
    <description>The percentages of subjects with at least 4-fold increase in hSBA titers against four different strains of N.meningitidis serogroup B, after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine.
4-fold increase is defined as follows;
for subjects with a prevaccination hSBA &lt; 1:2, a postvaccination hSBA ≥ 1:8, for subjects with a prevaccination hSBA ≥ 1:2, at least a 4-fold increase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The hSBA GMTs Against N.Meningitidis serogroupB, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.</measure>
    <time_frame>Day 1 and one month after the second vaccination (Day 91)</time_frame>
    <description>The hSBA GMTs against N.meningitidis serogroup B after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Geometric Mean Ratio of Post vs Pre Vaccination GMTs Against N.Meningitidis Serogroup B, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.</measure>
    <time_frame>One month after the second vaccination/prevaccination (Day 91/day 1)</time_frame>
    <description>The geometric mean ratio (GMR) of post vaccination versus pre vaccination GMTs against N.meningitidis serogroup B after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Reporting Solicited Adverse Events After Receiving Any Vaccination in This Study.</measure>
    <time_frame>Day 1 through day 7 after any vaccination</time_frame>
    <description>The number of subjects reporting solicited local and systemic adverse events and other indicators of reactogenicity after vaccination with ABCWY+OMV, ABCWY+qOMV or rMenB+OMV or MenACWY.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Reporting Unsolicited Adverse Events After Receiving Any Vaccination in This Study.</measure>
    <time_frame>Throughout the study ( Day 1 to Day 241)</time_frame>
    <description>The number of subjects reporting unsolicited AEs after vaccination with ABCWY+OMV, ABCWY+qOMV, rMenB+OMV or MenACWY.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">484</enrollment>
  <condition>Invasive Meningococcal Disease</condition>
  <arm_group>
    <arm_group_label>ABCWY+OMV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group received two doses of &quot;Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine&quot; plus Outer Membrane Vesicles (OMV) administered two months apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABCWY+qOMV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group received two doses of &quot;Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine&quot; plus one quarter dose of Outer Membrane Vesicles (qOMV) administered two months apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rMenB+OMV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this group received two doses of &quot;Meningococcal (group B) multicomponent recombinant adsorbed vaccine&quot;,administered two months apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenACWY</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this group received a dose of placebo followed by one dose of &quot;Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine&quot; administered two months later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.</intervention_name>
    <description>Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus OMV.</description>
    <arm_group_label>ABCWY+OMV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.</intervention_name>
    <description>Two injections of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.</description>
    <arm_group_label>rMenB+OMV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.</intervention_name>
    <description>One injection of saline solution placebo and one of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.</description>
    <arm_group_label>MenACWY</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.</intervention_name>
    <description>Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus a quarter dose of OMV.</description>
    <arm_group_label>ABCWY+qOMV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adolescents aged 10 through 25 years of age inclusive at the time of
             enrollment.

        Exclusion Criteria:

          -  History of any meningococcal vaccine administration;

          -  Current or previous, confirmed or suspected disease caused by N. meningitidis;

          -  Pregnant or nursing (breastfeeding) mothers;

          -  Females of childbearing age who have not used or do not plan to use acceptable birth
             control measures, for the duration of the study;

          -  Any serious, chronic, or progressive disease;

          -  Known or suspected impairment/alteration of the immune system;

          -  Receipt of blood, blood products and/or plasma derivatives, or a parenteral
             immunoglobulin preparation within the previous 90 days;

          -  History of severe allergic reactions after previous vaccinations or hypersensitivity
             to any vaccine component.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Clinical Therapeutics, 806 St. Vincent's Drive, Suite 615</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madera Family Medical Group,1111 West 4th Street</name>
      <address>
        <city>Madera</city>
        <state>California</state>
        <zip>93637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Trials LLC, 16660 Paramount Blvd, Suite 301</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Pediatric/Adult Research, 201 south 5th street</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bluegrass Clinical Research Inc.5512 Bardstown Road, Suite 2</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Pediatric Research Association, 7371 Brandt Pike, Suite C</name>
      <address>
        <city>Huber Heights</city>
        <state>Ohio</state>
        <zip>45424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Pediatric Research Association, 1775 Delco Park Drive</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Focus Research Group,201 Signature Place</name>
      <address>
        <city>Lebanon</city>
        <state>Tennessee</state>
        <zip>37087</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczna Przychodnia Lekarska Internistyczno-Pediatryczna,,Juniperus&quot;s.c, ul.Kościuszki 41</name>
      <address>
        <city>Izabelin (Warszawa)</city>
        <zip>05-080</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ HIPOKRATES II.sp.zo.o, ul.Pachonskiego 12</name>
      <address>
        <city>Kraków</city>
        <zip>31-223</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ PRAKTIMED Sp.zo.o, ul.Strzelców 15</name>
      <address>
        <city>Kraków</city>
        <zip>31-422</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Pediatrii Centrum Medycznego Kształcenia PodyplomowegoSzpital Bielański, ul. Cegłowska 80</name>
      <address>
        <city>Warszawa</city>
        <zip>01-809</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Pediatrii i Chorób Infekcyjnych, ul.O.Bujwida 44</name>
      <address>
        <city>Wrocław</city>
        <zip>50-354</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2011</study_first_submitted>
  <study_first_submitted_qc>January 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2011</study_first_posted>
  <results_first_submitted>January 31, 2014</results_first_submitted>
  <results_first_submitted_qc>September 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 26, 2014</results_first_posted>
  <last_update_submitted>September 19, 2014</last_update_submitted>
  <last_update_submitted_qc>September 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Meningococcal</keyword>
  <keyword>Seroresponse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All enrolled subjects were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ABCWY+OMV</title>
          <description>Subjects in this group received two doses of ABCWY+OMV combination vaccine, administered two months apart.</description>
        </group>
        <group group_id="P2">
          <title>ABCWY+qOMV</title>
          <description>Subjects in this group received two doses of ABCWY+qOMV combination vaccine, administered two months apart.</description>
        </group>
        <group group_id="P3">
          <title>rMenB +OMV</title>
          <description>Subjects in this group received two doses of rMenB + OMV vaccine,administered two months apart.</description>
        </group>
        <group group_id="P4">
          <title>ACWY</title>
          <description>Subjects in this group received one dose of placebo followed by one dose of MenACWY vaccine two months later.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="121"/>
                <participants group_id="P3" count="122"/>
                <participants group_id="P4" count="121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="109"/>
                <participants group_id="P4" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inappropriate enrollment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Anaysis was done on the All Enrolled Population, ie, all subjects who signed an informed consent/assent, undergone screening procedure(s) and were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>ABCWY+OMV</title>
          <description>Subjects in this group received two doses of ABCWY+OMV combination vaccine, administered two months apart.</description>
        </group>
        <group group_id="B2">
          <title>ABCWY+qOMV</title>
          <description>Subjects in this group received two doses of ABCWY+qOMV combination vaccine, administered two months apart.</description>
        </group>
        <group group_id="B3">
          <title>rMenB +OMV</title>
          <description>Subjects in this group received two doses of rMenB + OMV vaccine,administered two months apart.</description>
        </group>
        <group group_id="B4">
          <title>ACWY</title>
          <description>Subjects in this group received one dose of placebo followed by one dose of MenACWY vaccine two months later.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="120"/>
            <count group_id="B2" value="121"/>
            <count group_id="B3" value="122"/>
            <count group_id="B4" value="121"/>
            <count group_id="B5" value="484"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.7" spread="4.7"/>
                    <measurement group_id="B2" value="15.1" spread="4.9"/>
                    <measurement group_id="B3" value="15.3" spread="4.9"/>
                    <measurement group_id="B4" value="15.0" spread="5.1"/>
                    <measurement group_id="B5" value="15.0" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects With a Seroresponse Against N.Meningitidis Serogroups A,C,W-135,Y, After Receiving Different Formulations of MenABCWY Combination Vaccine.</title>
        <description>Non-inferiority of immune response of two doses of two different formulations of MenABCWY vaccine to a single dose of MenACWY vaccine as measured by the percentage of subjects with hSBA seroresponse against N.meningitidis serogroups A,C,W and Y.
Seroresponse is defined as:
For subjects with a pre-vaccination hSBA titer &lt; 1:4, a post-vaccination hSBA titer ≥ 1:8;
For subjects with a pre-vaccination hSBA titer ≥ 1:4, an increase in hSBA titer of at least four times the prevaccination titer.
Functional bactericidal antibodies directed against serogroups A,C,W,Y meningococci were measured with a serum bactericidal activity assay using human serum as the source of exogenous complement (hSBA).</description>
        <time_frame>One month after the second vaccination (Day 91)</time_frame>
        <population>Analysis was done on the per protocol population, immunogenicity, i.e subjects who received correct vaccines in both the visits; provided evaluable serum sample pre and post vaccination with assay results available for at least one serogroup and/or strain and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY+OMV</title>
            <description>Subjects in this group received two doses of ABCWY+OMV combination vaccine, administered two months apart.</description>
          </group>
          <group group_id="O2">
            <title>ABCWY+qOMV</title>
            <description>Subjects in this group received two doses of ABCWY+qOMV combination vaccine, administered two months apart.</description>
          </group>
          <group group_id="O3">
            <title>ACWY</title>
            <description>Subjects in this group received one dose of placebo followed by one dose of MenACWY vaccine two months later.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With a Seroresponse Against N.Meningitidis Serogroups A,C,W-135,Y, After Receiving Different Formulations of MenABCWY Combination Vaccine.</title>
          <description>Non-inferiority of immune response of two doses of two different formulations of MenABCWY vaccine to a single dose of MenACWY vaccine as measured by the percentage of subjects with hSBA seroresponse against N.meningitidis serogroups A,C,W and Y.
Seroresponse is defined as:
For subjects with a pre-vaccination hSBA titer &lt; 1:4, a post-vaccination hSBA titer ≥ 1:8;
For subjects with a pre-vaccination hSBA titer ≥ 1:4, an increase in hSBA titer of at least four times the prevaccination titer.
Functional bactericidal antibodies directed against serogroups A,C,W,Y meningococci were measured with a serum bactericidal activity assay using human serum as the source of exogenous complement (hSBA).</description>
          <population>Analysis was done on the per protocol population, immunogenicity, i.e subjects who received correct vaccines in both the visits; provided evaluable serum sample pre and post vaccination with assay results available for at least one serogroup and/or strain and had no major protocol violations.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A (N=88, 83, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="81" upper_limit="95"/>
                    <measurement group_id="O2" value="92" lower_limit="83" upper_limit="97"/>
                    <measurement group_id="O3" value="73" lower_limit="62" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (N=86, 84, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="89" upper_limit="99"/>
                    <measurement group_id="O2" value="93" lower_limit="85" upper_limit="97"/>
                    <measurement group_id="O3" value="63" lower_limit="51" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W-135 (N=75, 73, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="69" upper_limit="88"/>
                    <measurement group_id="O2" value="84" lower_limit="73" upper_limit="91"/>
                    <measurement group_id="O3" value="65" lower_limit="52" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (N=65, 70, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="83" upper_limit="97"/>
                    <measurement group_id="O2" value="90" lower_limit="80" upper_limit="96"/>
                    <measurement group_id="O3" value="75" lower_limit="62" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of seroresponse against N.meningitidis serogroup A of two doses of MenABCWY combination vaccine to that of one dose of MenACWY vaccine.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The immune response of ABCWY+OMV group was considered to be non-inferior to that of ACWY group if the lower limit of the two-sided 95% confidence interval on the difference between groups in percentage of subjects with seroresponse is greater than -10% for each of A, C, W-135and Y serogroups, at 30 days after the last vaccination.</non_inferiority_desc>
            <param_type>Group Difference % (ABCWY+OMV - ACWY)</param_type>
            <param_value>16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5</ci_lower_limit>
            <ci_upper_limit>29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of seroresponse against N.meningitidis serogroup C of two doses of ABCWY+OMV combination vaccine to that of one dose of MenACWY vaccine.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The immune response of ABCWY+OMV group was considered to be non-inferior to that of ACWY group if the lower limit of the two-sided 95% confidence interval on the difference between MenABCWY and MenACWY groups in percentage of subjects with seroresponse is greater than -10% for each of A, C, W-135and Y serogroups, at 30 days after the last vaccination.</non_inferiority_desc>
            <param_type>Group Difference % (ABCWY+OMV - ACWY)</param_type>
            <param_value>32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>21</ci_lower_limit>
            <ci_upper_limit>44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of seroresponse against N.meningitidis serogroup W-135 of two doses of ABCWY+OMV combination vaccine to that of one dose of MenACWY vaccine.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The immune response of ABCWY+OMV group was considered to be non-inferior to that of ACWY group if the lower limit of the two-sided 95% confidence interval on the difference between groups in percentage of subjects with seroresponse is greater than -10% for each of A, C, W-135and Y serogroups, at 30 days after the last vaccination.</non_inferiority_desc>
            <param_type>Group Difference % (ABCWY+OMV - ACWY)</param_type>
            <param_value>15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of seroresponse against N.meningitidis serogroup Y of two doses MenABCWY combination vaccine to that of one dose of MenACWY vaccine.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The immune response of ABCWY+OMV group was considered to be non-inferior to that of ACWY group if the lower limit of the two-sided 95% confidence interval on the difference between groups in percentage of subjects with seroresponse is greater than -10% for each of A, C, W-135and Y serogroups, at 30 days after the last vaccination.</non_inferiority_desc>
            <param_type>Group Difference % (ABCWY+OMV - ACWY)</param_type>
            <param_value>18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5</ci_lower_limit>
            <ci_upper_limit>31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of seroresponse against N.meningitidis serogroup A of two doses of MenABCWY+qOMV combination vaccine to that of one dose of MenACWY vaccine.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The immune response of MenABCWY+qOMV group was considered to be non-inferior to that of ACWY group if the lower limit of the two-sided 95% confidence interval on the difference between groups in percentage of subjects with seroresponse is greater than -10% for each of A, C, W-135and Y serogroups, at 30 days after the last vaccination.</non_inferiority_desc>
            <param_type>Group Difference % (ABCWY+qOMV - ACWY)</param_type>
            <param_value>18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7</ci_lower_limit>
            <ci_upper_limit>30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of seroresponse against N.meningitidis serogroup C of two doses of MenABCWY+qOMV combination vaccine to that of one dose of MenACWY vaccine.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The immune response of MenABCWY+qOMV group was considered to be non-inferior to that of MenACWY group if the lower limit of the two-sided 95% confidence interval on the difference between groups in percentage of subjects with seroresponse is greater than -10% for each of A, C, W-135and Y serogroups, at 30 days after the last vaccination.</non_inferiority_desc>
            <param_type>Group Difference % (ABCWY+qOMV - ACWY)</param_type>
            <param_value>30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18</ci_lower_limit>
            <ci_upper_limit>42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of seroresponse against N.meningitidis serogroup W-135 of two doses of MenABCWY+qOMV combination vaccine to that of one dose of MenACWY vaccine.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The immune response of MenABCWY+qOMV group was considered to be non-inferior to that of MenACWY group if the lower limit of the two-sided 95% confidence interval on the difference between groups in percentage of subjects with seroresponse is greater than -10% for each of A, C, W-135and Y serogroups, at 30 days after the last vaccination.</non_inferiority_desc>
            <param_type>Group Difference % (ABCWY+qOMV - ACWY)</param_type>
            <param_value>19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4</ci_lower_limit>
            <ci_upper_limit>33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of seroresponse against N.meningitidis serogroup Y of two doses of MenABCWY+qOMV combination vaccine to that of one dose of MenACWY vaccine.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The immune response of MenABCWY+qOMV group was considered to be non-inferior to that of MenACWY group if the lower limit of the two-sided 95% confidence interval on the difference between groups in percentage of subjects with seroresponse is greater than -10% for each of A, C, W-135and Y serogroups, at 30 days.</non_inferiority_desc>
            <param_type>Group Difference % (ABCWY+qOMV - ACWY)</param_type>
            <param_value>15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3</ci_lower_limit>
            <ci_upper_limit>29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Titers ≥ 1:8 Against N.Meningitidis Serogroups A,C,W-135 and Y, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.</title>
        <description>Percentages of subjects with hSBA titers ≥ 1:8 against N.meningitidis serogroups A,C,W-135 and Y, after two doses of either ABCWY+OMV or ABCWY+qOMV combination vaccine or one dose of MenACWY vaccine.</description>
        <time_frame>Day 1 and one month after second vaccination (Day 91)</time_frame>
        <population>Analysis was done on the per protocol population, immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY+OMV</title>
            <description>Subjects in this group received two doses of ABCWY+OMV combination vaccine, administered two months apart.</description>
          </group>
          <group group_id="O2">
            <title>ABCWY+qOMV</title>
            <description>Subjects in this group received two doses of ABCWY+qOMV combination vaccine, administered two months apart.</description>
          </group>
          <group group_id="O3">
            <title>ACWY</title>
            <description>Subjects in this group received one dose of placebo followed by one dose of MenACWY vaccine two months later.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titers ≥ 1:8 Against N.Meningitidis Serogroups A,C,W-135 and Y, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.</title>
          <description>Percentages of subjects with hSBA titers ≥ 1:8 against N.meningitidis serogroups A,C,W-135 and Y, after two doses of either ABCWY+OMV or ABCWY+qOMV combination vaccine or one dose of MenACWY vaccine.</description>
          <population>Analysis was done on the per protocol population, immunogenicity.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="3" upper_limit="15"/>
                    <measurement group_id="O2" value="6" lower_limit="2" upper_limit="13"/>
                    <measurement group_id="O3" value="1" lower_limit="0.033" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men A (Day 91; N=88, 83, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="86" upper_limit="97"/>
                    <measurement group_id="O2" value="95" lower_limit="88" upper_limit="99"/>
                    <measurement group_id="O3" value="73" lower_limit="62" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (Day 1; N=88, 85, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="25" upper_limit="46"/>
                    <measurement group_id="O2" value="35" lower_limit="25" upper_limit="46"/>
                    <measurement group_id="O3" value="32" lower_limit="21" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (Day 91; N=86, 84, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O3" value="83" lower_limit="73" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W-135 (Day 1; N=86, 79, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66" lower_limit="55" upper_limit="76"/>
                    <measurement group_id="O2" value="58" lower_limit="47" upper_limit="69"/>
                    <measurement group_id="O3" value="51" lower_limit="39" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W-135 (Day 91; N=77, 75, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O3" value="89" lower_limit="79" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (Day 1; N=89, 85, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="11" upper_limit="28"/>
                    <measurement group_id="O2" value="15" lower_limit="8" upper_limit="25"/>
                    <measurement group_id="O3" value="8" lower_limit="3" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (Day 91; N=65, 70, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="89" upper_limit="100"/>
                    <measurement group_id="O2" value="97" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O3" value="82" lower_limit="70" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The hSBA GMTs Against N.Meningitidis Serogroups A,C,W-135 and Y, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.</title>
        <description>The hSBA GMTs against N.meningitidis serogroups A,C,W-135 and Y, after two doses of either ABCWY+OMV or ABCWY+qOMV combination vaccine, or one dose of MenACWY vaccine.</description>
        <time_frame>Day 1 and one month after the second vaccination (Day 91)</time_frame>
        <population>Analysis was done on the per protocol population, immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY+OMV</title>
            <description>Subjects in this group received two doses of ABCWY+OMV combination vaccine, administered two months apart.</description>
          </group>
          <group group_id="O2">
            <title>ABCWY+qOMV</title>
            <description>Subjects in this group received two doses of ABCWY+qOMV combination vaccine, administered two months apart.</description>
          </group>
          <group group_id="O3">
            <title>ACWY</title>
            <description>Subjects in this group received one dose of placebo followed by one dose of MenACWY vaccine two months later.</description>
          </group>
        </group_list>
        <measure>
          <title>The hSBA GMTs Against N.Meningitidis Serogroups A,C,W-135 and Y, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.</title>
          <description>The hSBA GMTs against N.meningitidis serogroups A,C,W-135 and Y, after two doses of either ABCWY+OMV or ABCWY+qOMV combination vaccine, or one dose of MenACWY vaccine.</description>
          <population>Analysis was done on the per protocol population, immunogenicity.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" lower_limit="1.28" upper_limit="1.92"/>
                    <measurement group_id="O2" value="1.32" lower_limit="1.07" upper_limit="1.63"/>
                    <measurement group_id="O3" value="1.33" lower_limit="1.08" upper_limit="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men A (Day 91; N=88, 83, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="49" upper_limit="102"/>
                    <measurement group_id="O2" value="77" lower_limit="53" upper_limit="111"/>
                    <measurement group_id="O3" value="45" lower_limit="31" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (Day 1; N=88, 85, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.15" lower_limit="3.02" upper_limit="5.69"/>
                    <measurement group_id="O2" value="3.72" lower_limit="2.69" upper_limit="5.12"/>
                    <measurement group_id="O3" value="3.93" lower_limit="2.84" upper_limit="5.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (Day 91; N=86, 84, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214" lower_limit="148" upper_limit="309"/>
                    <measurement group_id="O2" value="187" lower_limit="129" upper_limit="272"/>
                    <measurement group_id="O3" value="55" lower_limit="38" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W-135 (Day 1; N=86, 79, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="8.88" upper_limit="22"/>
                    <measurement group_id="O2" value="10" lower_limit="6.45" upper_limit="16"/>
                    <measurement group_id="O3" value="6.58" lower_limit="4.11" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W-135 (Day 91; N=77, 75, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239" lower_limit="178" upper_limit="322"/>
                    <measurement group_id="O2" value="288" lower_limit="214" upper_limit="389"/>
                    <measurement group_id="O3" value="65" lower_limit="48" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (Day 1; N=89, 85, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.01" lower_limit="1.52" upper_limit="2.66"/>
                    <measurement group_id="O2" value="1.91" lower_limit="1.43" upper_limit="2.53"/>
                    <measurement group_id="O3" value="1.52" lower_limit="1.14" upper_limit="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (Day 91; N=65, 70, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149" lower_limit="95" upper_limit="234"/>
                    <measurement group_id="O2" value="129" lower_limit="83" upper_limit="201"/>
                    <measurement group_id="O3" value="46" lower_limit="29" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Titers ≥ 1:5 and ≥ 1:8 Against N.Meningitidis Serogroup B, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.</title>
        <description>The percentages of subjects with hSBA titers ≥ 1:5 and ≥ 1:8 against four different strains of N.meningitidis serogroup B, after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine.</description>
        <time_frame>Day 1 and one month after the second vaccination (Day 91)</time_frame>
        <population>Analysis was done on the per-protocol population, immunogenicity</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY+OMV</title>
            <description>Subjects in this group received two doses of ABCWY+OMV combination vaccine, administered two months apart.</description>
          </group>
          <group group_id="O2">
            <title>ABCWY+qOMV</title>
            <description>Subjects in this group received two doses of ABCWY+qOMV combination vaccine, administered two months apart.</description>
          </group>
          <group group_id="O3">
            <title>rMenB +OMV</title>
            <description>Subjects in this group received two doses of rMenB+OMV vaccine, administered two months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titers ≥ 1:5 and ≥ 1:8 Against N.Meningitidis Serogroup B, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.</title>
          <description>The percentages of subjects with hSBA titers ≥ 1:5 and ≥ 1:8 against four different strains of N.meningitidis serogroup B, after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine.</description>
          <population>Analysis was done on the per-protocol population, immunogenicity</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M14459 (Day 1; hSBA ≥1:5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="4" upper_limit="17"/>
                    <measurement group_id="O2" value="4" lower_limit="1" upper_limit="10"/>
                    <measurement group_id="O3" value="5" lower_limit="2" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (Day 91; hSBA ≥1:5; N=89, 85, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="53" upper_limit="74"/>
                    <measurement group_id="O2" value="71" lower_limit="60" upper_limit="80"/>
                    <measurement group_id="O3" value="82" lower_limit="72" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (Day 1; hSBA ≥1:5; N=90, 84, 91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1" upper_limit="9"/>
                    <measurement group_id="O2" value="14" lower_limit="8" upper_limit="24"/>
                    <measurement group_id="O3" value="4" lower_limit="1" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (Day 91; hSBA ≥1:5; N=86, 84, 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="70" upper_limit="88"/>
                    <measurement group_id="O2" value="80" lower_limit="70" upper_limit="88"/>
                    <measurement group_id="O3" value="93" lower_limit="86" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ 98/254 (Day 1; hSBA ≥1:5; N=89, 85, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1" upper_limit="10"/>
                    <measurement group_id="O2" value="1" lower_limit="0.03" upper_limit="6"/>
                    <measurement group_id="O3" value="3" lower_limit="1" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ 98/254 (Day 91; hSBA ≥1:5; N=89, 84, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="51" upper_limit="72"/>
                    <measurement group_id="O2" value="56" lower_limit="45" upper_limit="67"/>
                    <measurement group_id="O3" value="88" lower_limit="80" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (Day 1; hSBA ≥1:5; N=89, 84, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="17" upper_limit="36"/>
                    <measurement group_id="O2" value="27" lower_limit="18" upper_limit="38"/>
                    <measurement group_id="O3" value="23" lower_limit="15" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (Day 91; hSBA ≥1:5; N=88, 85, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="53" upper_limit="74"/>
                    <measurement group_id="O2" value="55" lower_limit="44" upper_limit="66"/>
                    <measurement group_id="O3" value="73" lower_limit="63" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (Day 1; hSBA ≥1:8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="2" upper_limit="12"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O3" value="4" lower_limit="1" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (Day 91; hSBA ≥1:8; N=89, 85, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="47" upper_limit="69"/>
                    <measurement group_id="O2" value="66" lower_limit="55" upper_limit="76"/>
                    <measurement group_id="O3" value="77" lower_limit="67" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (Day 1; hSBA ≥1:8; N=90, 84, 91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O2" value="13" lower_limit="7" upper_limit="22"/>
                    <measurement group_id="O3" value="4" lower_limit="1" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (Day 91; hSBA ≥1:8; N=86, 84, 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="69" upper_limit="87"/>
                    <measurement group_id="O2" value="79" lower_limit="68" upper_limit="87"/>
                    <measurement group_id="O3" value="91" lower_limit="83" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ 98/254 (Day 1; hSBA ≥ 8; N=89, 85, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1" upper_limit="10"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O3" value="3" lower_limit="1" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ 98/254 (Day 91; hSBA ≥1:8; N=89, 84, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="37" upper_limit="58"/>
                    <measurement group_id="O2" value="49" lower_limit="38" upper_limit="60"/>
                    <measurement group_id="O3" value="77" lower_limit="67" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (Day 1; hSBA ≥1:8; N=89, 84, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="11" upper_limit="28"/>
                    <measurement group_id="O2" value="20" lower_limit="12" upper_limit="30"/>
                    <measurement group_id="O3" value="14" lower_limit="8" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (Day 91; hSBA ≥1:8; N=88, 85, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="38" upper_limit="60"/>
                    <measurement group_id="O2" value="47" lower_limit="36" upper_limit="58"/>
                    <measurement group_id="O3" value="60" lower_limit="49" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With at Least 4-fold Increase in hSBA Titers Against N.Meningitidis Serogroup B, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.</title>
        <description>The percentages of subjects with at least 4-fold increase in hSBA titers against four different strains of N.meningitidis serogroup B, after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine.
4-fold increase is defined as follows;
for subjects with a prevaccination hSBA &lt; 1:2, a postvaccination hSBA ≥ 1:8, for subjects with a prevaccination hSBA ≥ 1:2, at least a 4-fold increase.</description>
        <time_frame>One month after the second vaccination (Day 91)</time_frame>
        <population>Analysis was done on the per-protocol population, immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY+OMV</title>
            <description>Subjects in this group received two doses of ABCWY+OMV combination vaccine, administered two months apart.</description>
          </group>
          <group group_id="O2">
            <title>ABCWY+qOMV</title>
            <description>Subjects in this group received two doses of ABCWY+qOMV combination vaccine, administered two months apart.</description>
          </group>
          <group group_id="O3">
            <title>rMenB+OMV</title>
            <description>Subjects in this group received two doses of rMenB+OMV vaccine, administered two months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With at Least 4-fold Increase in hSBA Titers Against N.Meningitidis Serogroup B, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.</title>
          <description>The percentages of subjects with at least 4-fold increase in hSBA titers against four different strains of N.meningitidis serogroup B, after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine.
4-fold increase is defined as follows;
for subjects with a prevaccination hSBA &lt; 1:2, a postvaccination hSBA ≥ 1:8, for subjects with a prevaccination hSBA ≥ 1:2, at least a 4-fold increase.</description>
          <population>Analysis was done on the per-protocol population, immunogenicity.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M14459</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="45" upper_limit="67"/>
                    <measurement group_id="O2" value="62" lower_limit="51" upper_limit="73"/>
                    <measurement group_id="O3" value="75" lower_limit="65" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (N=86, 83, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="69" upper_limit="87"/>
                    <measurement group_id="O2" value="70" lower_limit="59" upper_limit="79"/>
                    <measurement group_id="O3" value="88" lower_limit="79" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (N=88, 84, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="36" upper_limit="58"/>
                    <measurement group_id="O2" value="48" lower_limit="37" upper_limit="59"/>
                    <measurement group_id="O3" value="76" lower_limit="66" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (N=87, 84, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="19" upper_limit="38"/>
                    <measurement group_id="O2" value="25" lower_limit="16" upper_limit="36"/>
                    <measurement group_id="O3" value="42" lower_limit="32" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The hSBA GMTs Against N.Meningitidis serogroupB, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.</title>
        <description>The hSBA GMTs against N.meningitidis serogroup B after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine.</description>
        <time_frame>Day 1 and one month after the second vaccination (Day 91)</time_frame>
        <population>Analysis was done on the per-protocol population, immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY+OMV</title>
            <description>Subjects in this group received two doses of ABCWY+OMV combination vaccine, administered two months apart.</description>
          </group>
          <group group_id="O2">
            <title>ABCWY+qOMV</title>
            <description>Subjects in this group received two doses of ABCWY+qOMV combination vaccine, administered two months apart.</description>
          </group>
          <group group_id="O3">
            <title>rMenB +OMV</title>
            <description>Subjects in this group received two doses of rMenB + OMV vaccine, administered two months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The hSBA GMTs Against N.Meningitidis serogroupB, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.</title>
          <description>The hSBA GMTs against N.meningitidis serogroup B after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine.</description>
          <population>Analysis was done on the per-protocol population, immunogenicity.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M14459 (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" lower_limit="1.09" upper_limit="1.59"/>
                    <measurement group_id="O2" value="1.15" lower_limit="0.95" upper_limit="1.4"/>
                    <measurement group_id="O3" value="1.26" lower_limit="1.04" upper_limit="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M14459 (Day 91; N= 89, 85, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.24" lower_limit="6.19" upper_limit="14"/>
                    <measurement group_id="O2" value="11" lower_limit="7.51" upper_limit="17"/>
                    <measurement group_id="O3" value="17" lower_limit="11" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (Day 1; N=90, 84, 91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" lower_limit="0.82" upper_limit="1.42"/>
                    <measurement group_id="O2" value="1.72" lower_limit="1.29" upper_limit="2.28"/>
                    <measurement group_id="O3" value="1.14" lower_limit="0.86" upper_limit="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (Day 91; N= 86, 84, 90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="33" upper_limit="93"/>
                    <measurement group_id="O2" value="48" lower_limit="28" upper_limit="83"/>
                    <measurement group_id="O3" value="118" lower_limit="69" upper_limit="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ 98/254 (Day 1; N= 89, 85, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="1.03" upper_limit="1.39"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.94" upper_limit="1.28"/>
                    <measurement group_id="O3" value="1.21" lower_limit="1.04" upper_limit="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ 98/254 (Day 91; N= 89, 84, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.68" lower_limit="5.91" upper_limit="13"/>
                    <measurement group_id="O2" value="7.88" lower_limit="5.3" upper_limit="12"/>
                    <measurement group_id="O3" value="19" lower_limit="13" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (Day 1; N= 89, 84, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.55" lower_limit="1.86" upper_limit="3.49"/>
                    <measurement group_id="O2" value="2.45" lower_limit="1.76" upper_limit="3.4"/>
                    <measurement group_id="O3" value="2.13" lower_limit="1.54" upper_limit="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (Day 91; N= 88, 85, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.24" lower_limit="5.4" upper_limit="9.71"/>
                    <measurement group_id="O2" value="6.26" lower_limit="4.63" upper_limit="8.46"/>
                    <measurement group_id="O3" value="12" lower_limit="8.83" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Geometric Mean Ratio of Post vs Pre Vaccination GMTs Against N.Meningitidis Serogroup B, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.</title>
        <description>The geometric mean ratio (GMR) of post vaccination versus pre vaccination GMTs against N.meningitidis serogroup B after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine.</description>
        <time_frame>One month after the second vaccination/prevaccination (Day 91/day 1)</time_frame>
        <population>Analysis was done on the per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY+OMV</title>
            <description>Subjects in this group received two doses of ABCWY+OMV combination vaccine, administered two months apart.</description>
          </group>
          <group group_id="O2">
            <title>ABCWY+qOMV</title>
            <description>Subjects in this group received two doses of ABCWY+qOMV combination vaccine, administered two months apart.</description>
          </group>
          <group group_id="O3">
            <title>rMenB+OMV</title>
            <description>Subjects in this group received two doses of rMenB+OMV vaccine, administered two months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Geometric Mean Ratio of Post vs Pre Vaccination GMTs Against N.Meningitidis Serogroup B, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.</title>
          <description>The geometric mean ratio (GMR) of post vaccination versus pre vaccination GMTs against N.meningitidis serogroup B after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine.</description>
          <population>Analysis was done on the per-protocol population</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M14459</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.32" lower_limit="4.89" upper_limit="11"/>
                    <measurement group_id="O2" value="9.41" lower_limit="6.19" upper_limit="14"/>
                    <measurement group_id="O3" value="14" lower_limit="9.01" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M01-0240364 (N=86, 83, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="27" upper_limit="83"/>
                    <measurement group_id="O2" value="30" lower_limit="17" upper_limit="54"/>
                    <measurement group_id="O3" value="98" lower_limit="56" upper_limit="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ 98/254 (N=88, 84, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.44" lower_limit="5.06" upper_limit="11"/>
                    <measurement group_id="O2" value="6.91" lower_limit="4.64" upper_limit="10"/>
                    <measurement group_id="O3" value="16" lower_limit="11" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M07-0241084 (N=87, 84, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.94" lower_limit="2.15" upper_limit="4.02"/>
                    <measurement group_id="O2" value="2.59" lower_limit="1.88" upper_limit="3.58"/>
                    <measurement group_id="O3" value="5.16" lower_limit="3.76" upper_limit="7.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Reporting Solicited Adverse Events After Receiving Any Vaccination in This Study.</title>
        <description>The number of subjects reporting solicited local and systemic adverse events and other indicators of reactogenicity after vaccination with ABCWY+OMV, ABCWY+qOMV or rMenB+OMV or MenACWY.</description>
        <time_frame>Day 1 through day 7 after any vaccination</time_frame>
        <population>Analysis was done on the solicited safety set, ie all subjects in the all exposed set who provided postvaccination solicited AE data from day 1 (6 hours) through day 7. The all exposed set is defined as all subjects in the all enrolled population who actually received a study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY+OMV</title>
            <description>Subjects in this group received two doses of ABCWY+OMV combination vaccine, administered two months apart.</description>
          </group>
          <group group_id="O2">
            <title>ABCWY+qOMV</title>
            <description>Subjects in this group received two doses of ABCWY+qOMV combination vaccine, administered two months apart.</description>
          </group>
          <group group_id="O3">
            <title>rMenB+OMV</title>
            <description>Subjects in this group received two doses of rMenB+OMV vaccine, administered two months apart.</description>
          </group>
          <group group_id="O4">
            <title>ACWY</title>
            <description>Subjects in this group received one dose of placebo followed by one dose of MenACWY vaccine two months later.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Reporting Solicited Adverse Events After Receiving Any Vaccination in This Study.</title>
          <description>The number of subjects reporting solicited local and systemic adverse events and other indicators of reactogenicity after vaccination with ABCWY+OMV, ABCWY+qOMV or rMenB+OMV or MenACWY.</description>
          <population>Analysis was done on the solicited safety set, ie all subjects in the all exposed set who provided postvaccination solicited AE data from day 1 (6 hours) through day 7. The all exposed set is defined as all subjects in the all enrolled population who actually received a study vaccination.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="115"/>
                <count group_id="O4" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site erythema (N=107, 110, 115, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration (N=107, 110, 115, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="107"/>
                    <measurement group_id="O4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ( &gt;= 38C )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically attended fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prophylactic use of antipyretic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Therapeutic use of antipyretic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Reporting Unsolicited Adverse Events After Receiving Any Vaccination in This Study.</title>
        <description>The number of subjects reporting unsolicited AEs after vaccination with ABCWY+OMV, ABCWY+qOMV, rMenB+OMV or MenACWY.</description>
        <time_frame>Throughout the study ( Day 1 to Day 241)</time_frame>
        <population>Analysis was done on the unsolicited safety set, ie, all subjects in the all exposed set who provided postvaccination unsolicited AE data.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY+OMV</title>
            <description>Subjects in this group received two doses of ABCWY+OMV combination vaccine, administered two months apart.</description>
          </group>
          <group group_id="O2">
            <title>ABCWY+qOMV</title>
            <description>Subjects in this group received two doses of ABCWY+qOMV combination vaccine, administered two months apart.</description>
          </group>
          <group group_id="O3">
            <title>rMenB+OMV</title>
            <description>Subjects in this group received two doses of rMenB+OMV vaccine, administered two months apart.</description>
          </group>
          <group group_id="O4">
            <title>ACWY</title>
            <description>Subjects in this group received one dose of placebo followed by one dose of MenACWY vaccine two months later.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Reporting Unsolicited Adverse Events After Receiving Any Vaccination in This Study.</title>
          <description>The number of subjects reporting unsolicited AEs after vaccination with ABCWY+OMV, ABCWY+qOMV, rMenB+OMV or MenACWY.</description>
          <population>Analysis was done on the unsolicited safety set, ie, all subjects in the all exposed set who provided postvaccination unsolicited AE data.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="120"/>
                <count group_id="O4" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs (from day 1 to 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related AEs (day 1 to 30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AEs (day 31 to 60 or study termination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least poss.rel.AEs(day 31 to 60 or study term.)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE from day 1 to 91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least poss.rel.AEs(day 1 to 91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically attended AEs (day 92 to 241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>possibly related med.attend.AEs (day 92-241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs (Day 1 to Day 241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possibly/probably related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to withdrawal (Day 1 to Day 241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths (Day 1 to Day 241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Desirability Index for Each Vaccine Group, Based on Immunogenicity and Reactogenicity Parameters.</title>
        <description>The overall desirability index (DI) used to identify the optimal formulation of the combination vaccine was based on immunogenicity and reactogenicity parameters (on a scale of 0 to 1, with 0 for an undesirable response and 1 for a highly desirable response) as follows: Between-group ratios of hSBA GMTs were calculated, adjusted for prevaccination titer and center, against serogroups A, C, W, and Y (ABCWY+OMV group or ABCWY+qOMV group vs. Placebo/ACWY group) and against the 4 serogroup B test strains (ABCWY+OMV group or ABCWY+qOMV group vs. rMenB+OMV group). Reactogenicity was measured by the percentage of doses associated with severe local and systemic solicited AEs within 3 days following vaccination. Each immunogenicity and reactogenicity endpoint was assigned its own DI based on predefined desirability functions. The overall DI was calculated using the weighted geometric mean of the DI values of each of the ten parameters to derive an overall DI for each formulation.</description>
        <time_frame>One month after the second vaccination (Day 91)</time_frame>
        <population>Analysis was done on the Per Protocol Set - desirability, ie, all subjects who :
correctly received the vaccine at Visit 1 and Visit 2, provided evaluable serum samples pre- (Visit 1) and post-vaccination (Visit 3), provided post-vaccination solicited adverse event data an had no major protocol violation as defined prior to unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCWY+OMV</title>
            <description>Subjects in this group received two doses of ABCWY+OMV combination vaccine, administered two months apart.</description>
          </group>
          <group group_id="O2">
            <title>ABCWY+qOMV</title>
            <description>Subjects in this group received two doses of ABCWY+qOMV combination vaccine, administered two months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Desirability Index for Each Vaccine Group, Based on Immunogenicity and Reactogenicity Parameters.</title>
          <description>The overall desirability index (DI) used to identify the optimal formulation of the combination vaccine was based on immunogenicity and reactogenicity parameters (on a scale of 0 to 1, with 0 for an undesirable response and 1 for a highly desirable response) as follows: Between-group ratios of hSBA GMTs were calculated, adjusted for prevaccination titer and center, against serogroups A, C, W, and Y (ABCWY+OMV group or ABCWY+qOMV group vs. Placebo/ACWY group) and against the 4 serogroup B test strains (ABCWY+OMV group or ABCWY+qOMV group vs. rMenB+OMV group). Reactogenicity was measured by the percentage of doses associated with severe local and systemic solicited AEs within 3 days following vaccination. Each immunogenicity and reactogenicity endpoint was assigned its own DI based on predefined desirability functions. The overall DI was calculated using the weighted geometric mean of the DI values of each of the ten parameters to derive an overall DI for each formulation.</description>
          <population>Analysis was done on the Per Protocol Set - desirability, ie, all subjects who :
correctly received the vaccine at Visit 1 and Visit 2, provided evaluable serum samples pre- (Visit 1) and post-vaccination (Visit 3), provided post-vaccination solicited adverse event data an had no major protocol violation as defined prior to unblinding.</population>
          <units>Desirability index</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.306"/>
                    <measurement group_id="O2" value="0.325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited AEs were collected from Day 1to Day 7; unsolicited AEs and SAEs were collected throughout the study period (Day 1 to Day 241).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ABCWY+OMV</title>
          <description>Subjects in this group received two doses of rMenB(+ OMV_full dose) and MenACWY combination vaccine, administered two months apart.</description>
        </group>
        <group group_id="E2">
          <title>ABCWY+qOMV</title>
          <description>Subjects in this group received two doses of rMenB (+ OMV_1/4th dose)
+and MenACWY combination vaccine, administered two months apart.</description>
        </group>
        <group group_id="E3">
          <title>rMenB +OMV</title>
          <description>Subjects in this group received two doses of rMenB + OMV vaccine, administered two months apart.</description>
        </group>
        <group group_id="E4">
          <title>ACWY</title>
          <description>Subjects in this group received first dose of placebo followed by one dose of MenACWY vaccine administered two months apart.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>PERTUSSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ABNORMAL BEHAVIOUR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>SPERMATOCELE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="111" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="87" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Injection site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Injection site Induration</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Injection site Pain</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="107" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

